Aimmune Therapeutics, Inc. Sustainability Profile
Aimmune Therapeutics, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative treatments for food allergies. Founded in 2011, Aimmune has made significant strides in the industry, particularly with its flagship product, Palforzia, which is the first FDA-approved therapy for peanut allergy. This groundbreaking treatment offers a unique approach to desensitising patients, setting Aimmune apart in the competitive landscape of allergy therapeutics. With its headquarters in Brisbane, California, Aimmune operates primarily in North America and has established a strong market position through its commitment to research and development. The company’s dedication to advancing food allergy treatments has garnered recognition, positioning Aimmune as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Aimmune Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aimmune Therapeutics, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aimmune Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Nestlé S.A., which influences its climate commitments and initiatives. Aimmune's climate strategy is aligned with the broader sustainability goals set by Nestlé, including targets cascaded from Nestlé's initiatives related to the Science Based Targets initiative (SBTi), CDP, RE100, and Climate Action 100+. While Aimmune does not have its own documented reduction targets, it benefits from Nestlé's comprehensive climate action framework, which aims to significantly reduce greenhouse gas emissions across its operations. This includes commitments to achieve net-zero emissions by 2050 and to enhance sustainability practices throughout its supply chain. As part of the Nestlé family, Aimmune is expected to contribute to these overarching goals, although specific metrics for Aimmune's emissions or reduction targets are not disclosed at this time.
How Carbon Intensive is Aimmune Therapeutics, Inc.'s Industry?
How Carbon Intensive is Aimmune Therapeutics, Inc.'s Location?
Aimmune Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aimmune Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
